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Abstract: The innovation of drug delivery vehicles with controlled properties for cancer therapy
is the aim of most pharmaceutical research. This study aims to fabricate a new type of smart
biocompatible stealth-nanoliposome to deliver curcumin for cancer treatment. Herein, four different
types of liposomes (with/without pH-responsive polymeric coating) were synthesized via the
Mozafari method and then characterized with several tests, including dynamic light scattering (DLS),
Fourier-transform infrared spectroscopy (FTIR), Zeta potential, and field emission scanning electron
microscopes (FE-S EM). The loading and release profile of curcumin were evaluated in two pH of 7.4
and 6.6. Finally, the MTT assay was used to assess the cytotoxicity of the samples. FE-SEM results
revealed a mean size of about 40 and 50 nm for smart stealth-liposome and liposome, respectively.
The results of drug entrapment revealed that non-coated liposome had about 74% entrapment
efficiency, while it was about 84% for PEGylated liposomes. Furthermore, the drug released pattern
of the nanocarriers showed more controllable release in stealth-liposome in comparison to non-coated
one. The results of the cytotoxicity test demonstrated the toxicity of drug-loaded carriers on cancer
cells. Based on the results of this study, the as-prepared smart stealth pH-responsive nanoliposome
could be considered as a potential candidate for cancer therapy.
Keywords: smart drug delivery; mozafari method; herbal drug; liposome
1. Introduction
One of the most promising approaches for cancer treatment is the use of nanomaterials
as drug delivery vehicles. The tiny size of these materials leads to the facility of their moving
through the thinnest blood vessel and also the ability of their penetrating via the vessel to
the tissues in specific sites, especially cancerous tissues [1–3]. Moreover, they can protect
the drug cargo molecules from elimination by the immune system and release them at the
targeted site, which not only prevents side effect of drugs on the healthy tissues but also
improves the effectiveness of the drugs and thus causes a reduction in the dose [4–6].
Among the most applicable types of nanoparticles are liposomes, which are bilayer
nano-drug delivery systems that were innovated by Bangham and his coworkers in 1965 for
the first time. Liposomes are self-assembled spherical vesicles that consist of different types
of phospholipids and cholesterol that have the most structural similarity with the cellular
membrane [1,2]. Different types of phospholipid were considered for the preparation of
liposomes, which are categorized into two main classes: Natural phospholipids like egg
phosphatidylcholine and soy phosphatidylcholine (lecithin), and synthetic phospholipid,
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which contains a wide range of saturated and unsaturated phospholipids among the most
important of them is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) which can donate
the most stability to the liposomal structure and also improve drug loading and the released
pattern [3,4].
The specific structure of liposomes enables them to load both hydrophobic and hy-
drophilic drugs. In other words, the hydrophobic drugs could be placed inside the bilayer
structure, and hydrophilic ones could be encapsulated inside the central hollow part or
be loaded on the surface of the liposome [5–8]. Despite their different benefits, they have
a defect in their drug released pattern so that drug molecules show leakage from the
liposomal structure. Moreover, their rapid interaction with plasma proteins leads to their
elimination from the body circulation system. This has led to the design of new types of
the liposome, known as stealth liposome, in which the phospholipid bilayer is covered
by a polymeric layer [9–11]. Utilizing the polymeric shell could increase the circulation
time of liposomes, enhance their fluidity and stability, and reduce the uncontrollable drug
release from them [12].
One of the most prevalent polymeric shells used for the liposome covering is Polyethy-
lene glycol (PEG). This is an FDA-approved amphiphilic polymer with a hydrophilic
surface that can improve the hydrophilic property of liposomes. The PEGylated liposomes
could also show a protein resistance property that leads to improving blood circulation
and prevents their clearance by the mononuclear phagocyte system (MPS). Doxil™ and
Caelyx are two types of FDA-approved PEGylated liposomes containing doxorubicin as
the drug component [13–15].
To improve the drug molecules’ performance, eliminate their side effect, and decrease
the drug dosage, it is necessary to selectively accumulate the drug components in their
targeted sites. Indeed, there exist three main strategies for delivering the nanoparticles to
their targeted cancer tissue: Passive targeting, active targeting, and smart drug delivery.
Passive targeting is based on the physiological property of cancerous tissue, the enhanced
permeability and retention (EPR) effect, which increases the penetration of nanoparti-
cles through the cancerous vessel due to the increase in their intercellular distance [16].
Active targeting is based on the functionalizing nanocarriers with targeting ligands that
have an affinity to a receptor on the surface of cancer cells or a specific intercellular or-
ganelle. This targeting strategy works more effectively than an inactive one for cancer
treatment [17]. The last strategy is based on the drug release in a specific site due to the
structural change in response to the intrinsic (pH, and temperature) or extrinsic (light and
magnetic) stimulation [18].
It is confirmed in different literature that the pH of cancer tissues is a little lower
(6.5~7) than the pH of normal tissues (7.4), which results from a difference in the glucose
metabolic pathway [19,20]. This intrinsic feature of cancer tissue could be used for the
fabrication of smart pH-responsive drug delivery systems, which could release the drug
component due to the cleavage that occurs in their structure in response to the pH-change.
Based on these features, this study aimed to design and fabricate a new type of smart
pH-responsive stealth liposome for the delivery of curcumin as an anticancer drug. Cur-
cumin is a type of herbal drug extracted from the rhizome of Curcuma longa and shows
several biological activities, from anti-inflammatory, anti-oxidant, anti-diabetic, and anti-
atherosclerotic to anti-cancer, anti-angiogenic, and anti-metastatic [21]. Consequently, four
types of liposomes were fabricated (with/without stealth cover) by the Mozafari method
and characterized by different physicochemical and biological tests. Herein, citraconic
anhydride was chosen as a pH-responsive cross-linker between PEG and phospholipid
in the structure of nanoliposomes. During these tests, we also checked the effect of the
amount of cholesterol on the properties of nanoliposomes.
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2. Materials and Methods
2.1. Materials
Citraconic anhydride (CA) 98%, 1,2-distearoyl-sn-glycero-3-phosphocholine ≥ 99%
(DSPC), 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine ≥ 99% (DSPE), cholesterol
≥ 99%, pyridine 99.8%, dichloromethane ≥ 99.9%, diethyl ether ≥ 99.9%, and glycerol
≥ 99.0% were purchased from Sigma, USA. 4-Dimethylaminopyridine and dicyclohexyl-
carbodiimide were prepared from Merck, Germany. Polyethylene glycol (PEG-2000) was
received from Roth, Germany. Roswell Park Memorial Institute (RPMI) 1640 medium, fetal
bovine serum (FBS), phosphate buffer saline (PBS), penicillin-streptomycin, and trypsin-
EDTA were also received from BioIdea, Iran. The MCF7 and L929 cell lines were also
purchased from the Pasture Institute of Iran.
2.2. Methods
2.2.1. Preparation of pH-Responsive Agents
In this research, CA was used as a pH-responsive polymer to donate the smart feature
to the nanoliposome. For this purpose, CA was attached to the PEG and DSPE via two
different chemical reactions: Amidation and esterification. In detail, 34 mg of DSPE and
40 µL of CA were dissolved in 3 mL of pyridine and then added to 5 mL of dichloromethane.
After vigorously stirring the mixture for 24 h at room temperature, the products (DSPE-
-CIT-COOH) were precipitated in cold diethyl ether.
In the second step, the as-prepared DSPE- -CIT-COOH was dissolved in 5 mL of
dichloromethane, and then 50 mg of PEG was added to it. Certain amounts of DMAP
and DDC as the coupling agents were also added to the above mixture, and the final
solution was stirred for about 48 h under N2 atmosphere at room temperature. Then, it was
precipitated in cold diethyl ether and dialyzed against water for 72 h to remove the solvent
and all the non-reacted agents and final product (DSPE-citraconic-PEG (DSPE-CIT-PEG))
were dried with a freeze-drier (VaCo5, Zirbus, Bad Grund, Germany) [22].
2.2.2. Preparation of Liposome by the Mozafari Method
In this research, four different types of nanoliposomes were prepared with the aim
of the Mozafari method. For this purpose, different amounts of DSPC, DSPE, DSPE-CIT-
PEG, and cholesterol were weighted according to Table 1. Cholesterol was first dispersed
in water, and then it was warmed to 120 ◦C on a heater-stirrer for about 2 h until all
cholesterols were dissolved in the water.
Table 1. The amounts of different components of the nano-liposomes. DSPE: Distearoyl-sn-glycero-3-
phosphorylethanolamine; DSPC: Distearoyl-sn-glycero-3-phosphocholine; PEG: Polyethylene glycol.
Sample Cholesterol (µM) DSPE (µM) DSPC (µM) DSPE-CIT-PEG (µM)
1 5 5 53 -
2 10 5 53 -
3 5 - 53 5
4 10 - 53 5
In a separate three naked balloon, DSPC and DSPE-CIT-PEG/DSPE were added to
5 mL of water with 3% v/w glycerol, and the mixture was heated to be above the transition
temperature of DSPC (about 70 ◦C) under N2 atmosphere. When the phospholipid reagents
were completely dissolved in water, curcumin (with a concentration of 50 µg/mL of the
final solution) was added to the solution. After about 10 min, the cholesterol solution
was also added drop-wisely, and the final solution was vigorously stirred for about 1 h at
70 ◦C. Then, the temperature and the speed of the heater-stirrer were slowly decreased to
allow the components to get in touch with each other and the nanoliposome was prepared.
To decrease the size of the liposome, the solution was exposed to ultrasound waves for
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30 min and then kept at the above critical temperature (Tc) without stirring for 1 h to let
the liposomes be stable [23].
2.2.3. Characterization
To confirm the correct preparation of the DSPE-CIT-PEG and liposomes, different ana-
lytical tests were used. The size and morphology of the nanoliposomes were determined
by FE-SEM (MIRA3 TESCAN, Brno, Czech Republic). The powder samples were coated
with Au at first, and then their size and morphology were checked by the FE-SEM. FTIR
spectroscopy (400–4000 cm−1) was chosen to evaluate the surface characteristics of lipo-
somes with and without drug components and the correct preparation of DSPE-CIT-PEG
(JASCO 6300 spectroscope, Tokyo, Japan, transmission mode). To this end, the samples’
powder was mixed by KBr and after preparing the tablet, their absorbance was collected by
the FTIR instrument. Zeta sizer (HORIBA, scientific SZ100, Tokyo, Japan) was also applied
to determine the surface charge and hydrodynamic diameter of the samples. In this test,
samples were dispersed in deionized (DI) water via sonicating for at least 15 min, and then
their hydrodynamic size and surface charge were conducted by the zeta sizer.
2.2.4. Determining the Drug Loading and Released Profile
• Drug loading determining
Curcumin is a type of herbal drug with several excellent properties like anti-oxidant,
anti-bacterial, UV protective, and anticancer, but due to its low water solubility, it eliminates
from the circulation system rapidly. So, a water-soluble biocompatible carrier could enhance
the bioavailability of this drug. Based on this, a new formulation of liposome was selected in
this research for the delivery of this drug. The drug loading process was conducted during
the synthesis of liposomes since it might be absorbed in the interlayer space. To determine
the amount of non-loaded drugs, liposomes were centrifuged after the preparation process
to precipitate the liposomes. The supernatant, which contained non-loaded drugs, was
mixed with a certain amount of ethanol (99.9%) to dissolve the drug. Then the absorbance
of the solution was determined by UV-Visible spectroscopy (V670, Japan). The entrapment
efficiency of the loaded drug was calculated by the following equation [24]:
Entrapment Efficiency (%) =
MassTotal drug − Massnon−loaded drug
MassTotal drug
(1)
• pH-responsive drug release
The drug release behavior of the nano-liposomes in response to the pH-change was
determined at 25 ◦C and 37 ◦C over 5 days. For this purpose, a batch of 5 mg of liposomes
was dissolved in 3 mL of deionized water and put in the dialyzes bag with molecular
cut off 3.5 kD and placed in PBS solution with two different pH (7.4 and 6.6). After a
certain period (24, 48, 72, and 96 h), the PBS solution was replaced with fresh PBS. Then,
the drug containing PBS was centrifuged at 9000 RPM, the supernatant was discarded,
and the precipitate which contained the drug molecules was dissolved in alcohol, and the
absorbance of it was calculated to determine the amounts of the released drug.
2.2.5. Stability Assessment
The stability of nano-liposomes was determined by evaluating changes in the size (by
FE-SEM) and drug release ability for 3 months.
2.2.6. Cell Viability Assessment
MTT colorimetric assay was chosen to assess the cytotoxicity effect of drug-loaded
nano-liposomes. MTT assay is the most usual test used for this purpose, which is based
on the conversion of yellow MTT components to the purple formazan by an enzymatic
reaction inside the viable cells [25]. In this research, MCF-7 as the cancerous cell line, and
L929 as the Healthy cells were chosen, and the concentration of 8000 cells in 100 µL of
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medium were cultured in each well of 96 well plates, and then cells were incubated for
24 h at 37 ◦C and 5% CO2. After 24 h, the medium culture of each well was replaced by
fresh media containing different concentrations of drug-loaded nano-liposomes (25, 50,
and 100 µg/mL). Moreover, the concentration of 100 µg/mL of liposome without a drug
and two concentrations of free curcumin were also tested. After 24, 48, and 72 h of cells
incubation at 37 ◦C, the medium of each well was discarded, cells were washed with 100 µL
of PBS twice, and then 100 µL of pure media and 10 µL of MTT solution (5 mg/mL in PBS)
were added to each well and incubated for 3.5 h. After that, the media was replaced by
100 µL of DMSO and incubated for another 1 h, and then the absorbance of each well was
read at 493 nm by ELISA reader (Bio-Rad, Hercules, CA, USA) [26].
3. Results
3.1. Preparation of DSPE-CIT-PEG
In this research, the DSPE-CIT-PEG component was used as the pH-responsive agent
that degraded in acidic pH and turned to release the drugs in the acidic environment of the
cancerous tissues. On the other hand, the presence of this component in the structure of
liposomes led to the enhance in biocompatibility and water solubility of nano-liposomes.
Moreover, it could manage the drug released profile of the nano-liposomes in a more
controllable manner. This component was prepared based on a two-step reaction in which
amid and ester bonds were created between citraconic anhydride and DSPE and PEG,
respectively (Scheme 1).
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Scheme 1. Two‐step preparation of DSPE‐CIT‐PEG. Scheme 1. Two-step preparation of DSPE-CIT-PEG.
The correct preparation of this component was assessed by FTIR analysis (Figure 1).
In other words, the emergence of peaks at around 1570, 1690, 3300, and 3400 cm−1 in the
DSPE-CIT-PEG spectrum, which were attributed to the alkene group, amide bond, NH,
and OH groups, respectively, in response to the spectrum of PEG and DSPE, confirmed
the DSPE-CIT-PEG fabrication [22]. It is worth mentioning that the peaks of NH2 and OH
groups were clear in the spectrum of DSPE and PEG, respectively. Other peaks shown
in the figure are as follow: The alkane peaks at a wavenumber of about 2800–2900 cm−1,
respectively, that were presented in the spectrum of all three components, the ester bond at
around 1730 cm−1 in the spectrum of DSPE and DSPE-CIT-PEG [27], and the COC peak at
around 1100 cm−1 in the spectrum of PEG and DSPE-CIT-PEG [28,29].
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Figure 1. FTIR results of PEG, DSPE, and DSPE-CIT-PEG.
3.2. Fabrication of Nanoliposomes
In this research, the effect of the concentration of cholesterol and the polymeric shell
on the liposomal nanocarrier was evaluated. For this, four different types of nanoliposomes
(with/without drug molecules) were prepared based on the Mozafari method with two
different concentrations of cholesterol (5 and 10 M) and with/without PEG coating. The
main advantage of this method is that it leads to the preparation of safe liposomes since
the products of this method are prepared in the aquatic environment. Thus, they have
no toxic agents which may be present in the structure of liposomes derived from other
methods [30].
Different analytical analyses ere used for the evaluation of the as-prepared nanolipo-
somes. In the first step, FTIR was selected to evaluated differences between liposomes and
PEG-coated liposomes (stealth liposomes) with/without curc min (Figure 2). Figure 2a
shows the differences between the FTIR of lipos me and stealth lipos me. The presence of
NH, CONH, and C=C groups is ap arent at wavenumbers of 3 0 , 1690, and 15 0 cm− ,
ti l , i t t f t lt li i t t tr f t li -
. I i r , , ,
without curcumin) were also sho n. The absence of curc i at t , ,
623, and 3508 cm−1 which a ref rred to the aromatic C-O, olefinic C-H, C=C,
and C=O, C=C vibrations of the benzene ring, and phenolic O-H groups [31] peaks in the
spectrum of drug-loaded nanocarrier is a good reason w i h confirmed the encapsulation
of drugs in the interlayer spaces of the lip somes.
In the following section, the size and surface charge of the four types of nanoliposomes
were determined via the Zeta-sizer to evaluate the effect of cholesterol concentration on
the size of the nano-system. Table 2 shows the differences between the size and charge of
the nano-liposomes. Based on the results, the high negative zeta potential of all types of
nanoliposomes revealed their potential stability in the liquid media however, this charge
in the nanosystems with lower amounts of cholesterol was more negative in response to
other types. This negative charge is related to the presence of DSPE components in the
structure of liposome. Results also revealed that the negative charge of stealth liposomes
was lower than common liposomes in both types, which could be due to the interaction of
DSPE with CIT-PEG that could modulate its negative charge [32]. We also hypothesize that
this decrease may be due to the presence of OH groups on the surface of stealth liposomes
that interact with the H atoms of the surrounded aquatic environment temporary via week
hydrogen bonds and thus the emergence a local temporal positive charge on the surface
which reduces the negative charge.
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Figure 2. FTIR differences of (a) liposome and stealth liposome, and (b) liposome, stealth liposome,
liposome-drug, stealth liposome-drug, and curcumin.








Liposome 5:53:5 1 µm< - −49.1
10:53:5 474.6 nm 0.468 −41.1
Stealth pH-responsive
liposome
5:53:5 1 µm< - −47.6
10:53:5 323 nm 0.397 −34.2
On the other hand, the size of these nanoliposomes was changed with cholesterol
alteration so that, by increasing the concentrations of cholesterol, the size of liposomes
was decreased which is the same result of other researches. Based on the literature, the
concentration of cholesterol has a direct effect on the size, rigidity, and drug loading ability
of the liposomes, in such a way that it could decrease the size of liposomes in the low molar
ratios by affecting the structural properties and also increase the rigidity of liposomes at
high molar ratios, and thus a concentration rage was determined for this component to
prepared liposomes with an appropriate size and fluency [33,34].
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Based on the results of this section, the samples (liposome and stealth liposome) with
the higher molar ratio of cholesterol were selected for the further sections. The size and
morphology of the nanoliposomes with and without drug molecules were determined
by the FE-SEM analysis, and the results are shown in Figure 3. As it is clear in the figure,
using PEG as a cover for the liposomes turned to the production of nanosystems with more
distinctive morphology. In other words, in the absence of PEG, coating liposomes were
aggregated and had no recognizable spherical shape in the FE-SEM figure. The size of the
nanoliposomes was also determined, which was about 50 and 40 nm for the liposome and
stealth liposome, respectively.
















5:53:5  1 μm˂  ‐  −49.1 
10:53:5  474.6 nm  0.468  −41.1 
Stealth pH‐responsive lipo‐
some 
5:53:5  1 μm˂  ‐  −47.6 





























Figure 3. FE-SEM results of drug-loaded: (a) Stealth liposome and (b) liposome.
3.3. Determination of Entrapment Efficiency
The amounts of drug-loaded in the nano-liposomes were determined by the measure-
ments of the optical absorption of curcumin at 430 nm via UV-Visible spectroscopy. Table 3
shows the results of the entrapment efficiency of the nanoliposomes:
Table 3. Percentage of curcumin entrapment efficiency.







Results demonstrated that there was no significant difference between nanosystems
with different amounts of cholesterol. However, nanosystems with higher amounts of
cholesterol showed a little lower entrapment efficiency, which could be due to the en-
hancement that occurred in the structural strength of these liposomal systems that prevent
more drug loading. Moreover, the presence of the polymeric shell turned to improve drug
loading. We suggested that it may be due to the presence of drug molecules near the
hydrophobic chain of the polymers. It is revealed in other studies that cholesterol could
affect the amount of loading drug especially in the case of a hydrophobic one. In other
words, cholesterol competes with the drug components that are incorporated in the bilayer
space and decrease the loading amount of hydrophobic drugs [35].
3.4. pH-Responsive Drug Release
The drug released profile of nanoliposomes was determined in response to the en-
vironmental pH at 37 ◦C for 5 days (Figure 4). The results of this section confirmed the
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effectiveness of the PEGylation on controlling the drug released profile so that the common
form of liposome released approximately all 100% of its drug cargo at 37 ◦C in pH = 7.4
after 5 days, while this was about 61% for the stealth liposome with no drug released on
the first day. The pH-responsive behavior of the stealth liposomes was also confirmed
based on the results of the drug released. As it is clear in Figure 4b, the release of the drug
component at pH = 6.6 showed two part, a burst released part during the first 24 h and a
more controllable release in the following hours. At the first stage, the pH-responsive bond
of citraconic components was disrupted, which lead to the separation of CIT-PEG layer
from the liposomes [22]. This structural change turned to the release of drug components,
which were entrapped in the polymeric shell as well as part of drug components inside the
liposome. In the second stage, the drugs entrapped inside the liposome were released in a
controllable manner in response to the pH and due to the presence of DSPE components
that themselves played a pH-responsive role [36]. It is necessary to mention that the stealth
liposome had a better drug release profile in response to the common liposome, and it
could release nearly all of its components for 5 days [37].
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Figure 4. pH-responsive drug released pattern of (a) liposome and (b) stealth liposome at 37 ◦C.
3.5. luation
- r ared liposomes was determined after 3 months by monitor-
ing the changes that occurred in size and t r r l ased properties of them. Figure 5
shows the FE-SEM results of li oso es and stealth liposomes after 3 months. The results
of electron icroscopy revealed no changes in the size of both types of liposo es however,
aggregation occurred for both of them.
The drug release ability of liposomes and stealth liposomes was also investigated after
3 months (Figure 6). As it clear in the figure, the drug release profile of liposomes had
affected by the time, so that the capability of the drug released in normal pH was decreased,
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and in acid pH, it showed a burst release profile during just 3 days, which may represent
the instability of liposomes. In contrast to common liposomes, stealth liposomes could
preserve their released profile and released the drugs in a controllable manner at acidic pH
however, they showed some reduction in the drug released property, too.



















Figure 5. FE-SEM results of (a) stealth liposome and (b) liposome.















Figure 6. pH-responsive drug released profile of (a) liposome, and (b) stealth liposo e, after 3
months at 37 ◦C.
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3.6. MTT Assay
The biocompatibility of different concentrations of liposomes and stealth liposomes
was evaluated by MTT assay. In this test, drug-loaded nanoliposomes were exposed to
normal and cancerous cells, and their cytotoxicity effect was assessed during 24–72 h.
Figure 7a–c shows the cytotoxicity results of nanosystem on L929 cell line. As it is clear in
this figure, not drug-loaded nanoliposomes nor nanocarrier alone showed a cytotoxicity
effect against the normal cell line, while free drugs (in both concentrations) showed a
significant cytotoxicity effect. Moreover, these nanosystems turn to an increase in the
viability of the normal cells after 48 h, which could confirm the biocompatibility of them.











Figure 7. Results of MTT assay of liposome and stealth liposome after (a) 24 h, (b) 48 h, and (c) 7 h
on the L929 cell line (* p ≤ 0.05).
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The effect of nanoliposomes on the cell viability of the MCF7 cell line was also evalu-
ated during 24–72 h, and their results are shown in Figure 8a–c. Based on the results of
this test, both types of nanoliposome showed a cytotoxicity effect against the cancer cells
after 48 and 72 h moreover, the stealth liposomes had more cytotoxicity in comparison to
the common liposomes so that they showed 31% and 29% cytotoxicity after 72 h at the
concentration of 100 µg mL−1, respectively.












Figure 8. Results of MTT assay of liposome and stealth liposome after (a) 24 h, (b) 48 h, and (c) 72 h
on the MCF7 cell line (* p ≤ 0.05).
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4. Discussion
In this paper, a new type of pH-responsive liposome was introduced to deliver cur-
cumin to breast cancer tissue. In detail, four types of liposomes were fabricated via
conjugation of DSPE and DSPC, as the phospholipid components, with cholesterol. To
determine the effect of cholesterol on the stability and structure of liposomes, two con-
centrations of cholesterol were used for the fabrication of nanoliposomes. The results of
different tests revealed that the lower amount of cholesterol could affect the structural
features of nanoliposomes and lead to the production of unstable nanoparticles, which had
similarities with other researches. Indeed, it is confirmed that the presence of cholesterol
could affect the rigidity, fluidity, thickness, and stability of liposomes [34,38,39].
The nanoliposomes were prepared via the Mozafari method which is known as
one of the best methods for the production of nanoliposomes since no hazard solvent
is used for the preparation of the liposome by this method. The main aim of this study
was to introduce a novel smart stealth liposome for the delivery of hydrophobic drugs.
Utilizing the polymeric shell not only could enhance the stability and biocompatibility of
the nanoliposomes, but also improve their drug loading capacity [40]. Here, we fabricated a
type of pH-responsive nanoliposome using citraconic anhydride, which could be broken in
response to acidic pH. Indeed, it was the first work in which pH-responsive nanoliposomes
were fabricated by the Mozafari method for delivering curcumin to breast cancer tissues.
We test the effect of coating nanoliposome by CYT-PEG on its different properties,
and the results revealed that it could improve different features of the nanosystem. On the
other hand, it could reduce the size of nanoparticles, improve its drug loading, regulate
its drug release pattern, and enhance the stability of the particles however, the potential
charge of the nanoparticles was increased. The pH-responsibility of the nanoparticles was
also tested in two different pH: pH = 7.4, which is the normal pH of the body, and pH = 6.6,
which is the pH of cancerous tissues. It is worth mentioning that the presence of DSPE in
the structure of the uncoated nanoliposomes could donate a pH-responsible ability [38],
but they were non-stable liposomes with a burst released pattern at pH = 7.4 and unstable
released pattern during the storage. While coated nanoparticles had better stability during
the time, and could prevent drug release in the first 24 h at pH = 7.4 (which is the usual
time needed for delivery of drug components to the targeted site).
The synthesis of pH-responsive stealth nanoliposomes is a new research topic that
has received a lot of attention and several kinds of research have been done based on
it [41,42]. For instance, in 2016, Zhao et al. prepared a pH-responsive liposome as a
carrier of doxorubicin (DOX) for the treatment of glioblastoma. In this research, a type of
pH-responsive peptide (H7K (R2)2) was used to functionalized stealth liposomes. They
assessed the drug released pattern during 24 h in four different pH (5.5, 6, 6.5, and 7.4), and
their results revealed that most of the drug components were released from the liposome
during the first 8 h in the acidic environment while just 20% of them were released at a
normal pH [43]. In comparison to this study, the current work has a more controllable drug
release pattern and could release its drug components over a longer time, which could
improve the effectiveness of the drug in cancer treatment.
In 2018, Lee et al. fabricated a pH-responsive liposome via functionalizing hydro-
genated soy phosphatidylcholine (HSPC) by hyaluronic acid (HA) grafted with functional
3-diethylaminopropyl (DEAP) for the delivery of docetaxel (DTX) (a type of hydrophilic
drug). They tested the release process for 24 h and saw that their system showed burst
release during the first 4 h (for both normal and acidic pH), and after that, the release rate
decreased for both however, the release rate was faster in acidic pH [44]. In comparison to
this research, the liposome prepared in the current work had no release during the first
24 h at pH = 7.4, which makes it suitable for drug delivery application.
Curcumin is a type of hydrophobic herbal drugs with high potential application in the
field of pharmacy which is resulted from its various therapeutic activities. It was widely
used in different research as the anti-cancer drug for the treatment of different types of
cancer, but the hydrophobic nature of this component has limited its effectiveness. To
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overcome this limitation several types of nanocarrier were used till now, among them are
liposomes which could be prepared via different strategies [45]. In the current research,
we hypothesized to increase the bioavailability of curcumin in the microenvironment of
cancerous tissue via encapsulating it in pH-responsive nanoliposome.
In most of the studies, the active targeting method was used for the liposomal delivery
of curcumin to its targeted site [46,47]. The main difference between these studies and
the current work is that they just verified the release pattern in normal pH (7.40) or they
had the same release pattern in different pH, while this work showed a different release
rate. For instance, Mohammadi et al. in 2020 also fabricated a targeted nanoliposome for
delivery of curcumin to MCF7 cancer cells. The lack of polymeric shell and pH-responsive
agent in their nanosystem led to producing a similar curcumin releasing pattern in different
pH (5.5, 6.5, and 7.4). Moreover, most of the drug components were released during 15 h
which may cause a side effect on normal tissues [48]. While in the current work we did not
see any release during the first day in pH 7.4, which is the normal pH of the body.
In the field of pH-responsivity, the route of administration plays an important role
and could affect the type of material used. According to our knowledge, most of the
pH-responsive curcumin loaded liposomes were fabricated for oral administration of this
drug, which should show resistance against to acidic conditions of the stomach and release
their components in a basic condition. For instance, Leo et al. in 2020 prepared a type of pH-
responsive curcumin-loaded nanoliposomes for the aim of delivering the drug to the colon
cells through oral administration. In this study, the nonmetric liposomes were prepared
and coated by Eudragit S100 which is a pH-responsive shell that protects the liposomes
from the acidic pH of the stomach and dissolves at pH > 7.0 [49]. While the liposomes
prepared in the current work were suitable to be applied via blood administration. Indeed,
they were responsive to the weakly acidic condition of the tumor tissue and enhanced the
bio-availability of the curcumin in the tumor, while could limit the releasing of the drug in
normal pH (at least for the first 24 h).
The cytotoxicity results of coated and non-coated liposomes confirmed the effective-
ness of pH-responsive coating against cancerous tissues however, in vivo tests are needed
for more assurance. In other words, the presence of bicarbonate in the formulation of
media used for in vitro tests prevents the pH change during the test and could affect the
results of these tests.
5. Conclusions
In summary, four different types of liposomes (with and without the pH-responsive
agent) were fabricated via the Mozafari method via encapsulating curcumin between the
bilayer of nanoliposomes. Nanoliposomes were characterized by different physicochemical
methods. The FTIR results confirmed the preparation of DSPE-CIT-PEG component and
curcumin-loaded liposomes. The results of DLS tests revealed that nanoliposomes with a
lower amount of cholesterol had micron size and thus were not suitable for continuous
tests. The nanometric size liposomes drug released in response to pH changes was also
assessed, and its results showed coated liposomes had a controllable drug release pattern
even after 3 months which represents their stability during storage time. Moreover, these
pH-responsive stealth liposomes had better cytotoxicity against cancer cells. According
to these results, it could be concluded that this new type of smart liposome could be
considered as a good candidate for cancer therapy.
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